MDS patients who progressed to AML, have higher-risk MDS, with myeloblast count ≥ 20% and acquired/expanded abnormalities in TP53, RUNX1, or RAS genes [19]. This evidence concerns the gene RUNX1 and myelodysplastic syndrome.